NEW PRODUCTS
SKIN REJUVENATION
HAIR RESTORATION
MEDI ESTHETIC
HEALTH SCIENCE
SIGNATURE BRANDS
WOUND HEALING
Background
Clinical Data
In Vivo Test <<
Example 1
Example 2
Example 3
Commercial Markets
Product
MICRONEEDLE
M2 PEPTIDE
3D MINERALS
NOPAL JUICE
REINAHALEN
60 SECOND MIRACLES
AROSCA
SKINSHADE
HTA-7 (Reprotin)
MORE by ALION Lab <<
Brochure (46MB)
Download PDF Reader


In Vivo Test Results

ACT-1 Clinical Trials Decreased Wound Width & Gap Size

A small phase I study was conducted using either the ACT-1 or ACT-2 peptide as the active ingredient in separate pharmaceutical combination to treat chronic and acute wounds. The formulation vehicle for the ACT-1 peptide is called the ACT-1 Peptide Formulation and the formulation vehicle for the ACT-2 peptide is called the ACT-2 Peptide Formulation. Management elected to focus only on these two peptides due to limited financial resources.
The Phase I study involved patients with chronic or acute wounds to measure the wound healing response. For this study, under the supervision of a medical doctor, each patient applied either the ACT-1 Peptide Formulation or the ACT-2 Peptide Formulation as a topical gel over the entire wound once or twice daily. The patients were allowed to resume normal activities within reason throughout the study.
The research was conducted at two clinics: one in California, one in New York. The endpoints of the study are clearly seen in the patient history summary and photos. The patients involved in the study experienced a drastic reduction in wound size and/or complete healing of chronic and acute wounds and/or an accelerated healing rate. The photos contained in this book have not been retouched.


Examples

Example for Diabetic Foot Ulcer with Woundheal Master

Diabetic foot ulcer is a major complication of diabetes. People with diabetes show a 5- to 50-fold higher risk of nontraumatic amputation compared with individuals who do not suffer from diabetes. A diabetic foot ulcer is an open sore or wound that most commonly occurs on the bottom of the foot in approximately 15 percent of patients with diabetes. Of those who develop a foot ulcer, six percent will be hospitalized due to infection or other ulcer-related complication.

1. Clinical Trial : Patient JD

2. Clinical Trial #2: Patient AT


3. Clinical Trial #3: Patient PM